Enzyme inhibitors
AssigneeConsejo Superior de Investigaciones Cientificas
InventorsAna Martinez Gil, Ana Castro Morera, Maria Concepcion Martin Perez, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Francisco Jose Moreno Munoz, Francisco Wandosell Jurado
Life of this patent
Estimating the term…
Abstract
Compounds of general formula (I): 1 where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.
Claims29
Compounds of general formula (I):
- 27
- wherein:
- A is —C(R1)2—, —O— or —NR1—;
- E is —NR1— or —CR1R2— and the substituent R2 is absent if - - - is a second bond between E and G;
- G is —S—, —NR1— or —CR1R2— and the substituent R2 is absent if - - - is a second bond between E and G;
- - - - may be a second bond between E and G where the nature of E and G permits and E with G optionally then forms a fused aryl group;
- R1 and R2 are independently selected from hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, —(Z)n-aryl, heteroaryl, —OR3, —C(O)R3, —C(O)OR3, —(Z)n—C(O)OR3 and —S(O)t— or as indicated R2 can be such that E with G then form a fused aryl group;
- Z is independently selected from —C(R3)(R4)—, —C(O)—, —O—, —C(═NR3)—, —S(O)t— and N(R3)—;
- n is zero, one or two;
- t is zero, one or two;
- R3 and R4 are independently selected from hydrogen, alkyl, aryl and heterocyclic;
- and
- X and Y are independently selected from ═O, ═S, ═N(R3) and ═C(R1)(R2).
Dependencies are inferred from the claim text.